FDA Approves Ozempic for Type 2 Diabetes

Share this content:
FDA Approves Ozempic for Type 2 Diabetes
FDA Approves Ozempic for Type 2 Diabetes

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's insulin production and reduces appetite, the Associated Press reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 diabetes patients found those who took Ozempic had average reductions in long-term blood glucose levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Study Provides Estimates of U.S. Prevalence of Type 1, 2 Diabetes

Study Provides Estimates of U.S. Prevalence of Type ...

Prevalence of type 1 diabetes 0.5 percent, type 2 diabetes 8.5 percent among U.S. adults

Black Individuals at Highest Risk of Legal Intervention Injury

Black Individuals at Highest Risk of Legal Intervention ...

Increase in rates of injuries from 2005 to 2009, followed by a drop to 2015, returning to ~2005 levels

Research Links Doctor Burnout to Patient Safety Incidents

Research Links Doctor Burnout to Patient Safety Incidents

Physician burnout linked to increased risk of patient safety incidents, reduced patient satisfaction

is free, fast, and customized just for you!




Already a member?

Sign In Now »